SV Health Investors (“SVHI”), a healthcare and life sciences focused private investment firm, announces the acquisition of EpiVax, Inc. Headquartered in Providence, RI, EpiVax is a leading bioanalytical CRO specializing in immunogenicity risk assessments for pharmaceutical and biotech companies. EpiVax has been a pioneer in pre-clinical drug development for over 25 years, serving as a trusted scientific advisor to life sciences clients. EpiVax represents a new platform investment for SV Health Investors, building on SVHI’s deep experience in outsourced pharma services. Notable prior pharma services investments include Adimab, Clario (BioClinica), Celerion, and Leiters.
Read the full article: SV Health Investors Acquires EpiVax //
Source: https://www.businesswire.com/news/home/20260402771640/en/SV-Health-Investors-Acquires-EpiVax